Akoya Biosciences Inc (AKYA) - Total Liabilities
Based on the latest financial reports, Akoya Biosciences Inc (AKYA) has total liabilities worth $118.54 Million USD as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Akoya Biosciences Inc long-term investment allocation to see how much of total assets are deployed in long-term investments.
Akoya Biosciences Inc - Total Liabilities Trend (2019–2024)
This chart illustrates how Akoya Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Akoya Biosciences Inc asset portfolio.
Akoya Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Akoya Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
artnet AG Namens-Aktien o.N.
XETRA:ART
|
Germany | €29.69 Million |
|
Swiss Water Decaffeinated Coffee Inc
TO:SWP
|
Canada | CA$134.66 Million |
|
NPC Co. Ltd
KO:004250
|
Korea | ₩175.92 Billion |
|
Anam Electroni
KO:008700
|
Korea | ₩111.38 Billion |
|
Dhunseri Investments Limited
NSE:DHUNINV
|
India | Rs15.90 Billion |
|
Supremex Inc.
TO:SXP
|
Canada | CA$197.87 Million |
|
Minda Global Bhd
KLSE:5166
|
Malaysia | RM261.50 Million |
|
HY Energy Group Co Ltd
SHG:600387
|
China | CN¥924.38 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Akoya Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See AKYA net asset quality score to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.61 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -20.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Akoya Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Akoya Biosciences Inc (2019–2024)
The table below shows the annual total liabilities of Akoya Biosciences Inc from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $117.41 Million | -7.26% |
| 2023-12-31 | $126.60 Million | +7.79% |
| 2022-12-31 | $117.45 Million | +68.86% |
| 2021-12-31 | $69.56 Million | +17.71% |
| 2020-12-31 | $59.09 Million | -50.58% |
| 2019-12-31 | $119.57 Million | -- |
About Akoya Biosciences Inc
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions for transforming discovery, clinical research, and diagnostics in North America, the Asia-Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImag… Read more